Parameter
| Biomarker | Aβ42/40 ratio | Full name | Amyloid-β 42/40 ratio | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis, susceptibility | ||
| Disease | Liver Cirrhosis | Disease Subtypes | / | ||
| Organ | Liver | Test Sample / Technology Platform | CSF/Plasma (SIMOA, ELISA) | ||
| Pathobiological Mechanisms | Aβ42 aggregates into oligomers and plaques, leading to neurotoxicity; Aβ40 was relatively stable. Ratio reduction is A more reliable indicator of Aβ pathology than single indicator. | ||||
| Clinical Availability Status | Study validation/early clinical: CSF testing was included in the study criteria; Plasma testing is being validated on a large scale. | ||||
| Notes and Dynamics | Plasma Aβ42/40 is A hot spot for early screening and population screening, and it is expected to enter clinical practice. | ||||